In pre-market trading, shares are down 21% to $5.30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics’ dalzanemdor did not meet primary endpoint in Phase 2 study
- Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- CVS Health upgraded, Mobileye downgraded: Wall Street’s top analyst calls
- SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
- Sage Therapeutics announces discontinuation of SAGE-324 pact with Biogen